Ferring Pharmaceuticals Expands Gene Therapy Production
Ferring Pharmaceuticals has recently unveiled a remarkable advancement in its manufacturing capabilities with the opening of a new global manufacturing hub in Europe. This state-of-the-art facility, located in Kuopio, Finland, is specifically designed for the production of Adstiladrin, an innovative gene therapy intended for patients suffering from non-muscle invasive bladder cancer (NMIBC).
A New Era for Gene Therapy
This new facility is a game changer for Ferring Pharmaceuticals as it positions them to meet the growing global demand for this crucial treatment. Adstiladrin, also known as nadofaragene firadenovec-vncg, has gained regulatory approval in the U.S. for adult patients who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy.
As reported, Ferring is embarking on an ambitious clinical research program to further enhance the evidence base for Adstiladrin, preparing for potential regulatory submissions in various international markets. According to Bipin Dalmia, Global Head of Uro-Oncology and Urology Franchise, this facility ensures stable and sustainable global supply, catering to anticipated growth in demand.
Commitment to Innovation in Oncology
Armin Metzger, Executive Vice President and Chief Technical Operations Officer at Ferring Pharmaceuticals, emphasized that this investment exemplifies Ferring’s commitment to navigating complex manufacturing challenges. The facility incorporates advanced technology and sustainable practices aimed at reducing environmental impact, showcasing the company’s dedication to responsible production.
Understanding Non-Muscle Invasive Bladder Cancer
Non-muscle invasive bladder cancer is increasingly common, now ranking as the ninth most diagnosed cancer globally. This highlights an urgent need for innovative treatments like Adstiladrin, which turns the bladder cells into microfactories producing a protein that fights bladder cancer.
Approximately 75% of bladder cancers present as non-muscle invasive, creating a significant demand for effective therapeutic options, especially for patients who do not respond to conventional treatments like BCG.
Gene Therapy Process
Essentially, gene therapy involves modifying or manipulating the biological properties of cells to combat diseases. Techniques used can range from introducing new gene copies to replacing defective genes. Viral vectors, including the adenoviruses used in Adstiladrin, are particularly effective in delivering therapeutic genes directly to the targeted cells.
Global Presence and Future Prospects
Ferring Pharmaceuticals, a privately owned and research-driven biopharmaceutical group, prides itself on its contributions to specialized medicine, notably in the fields of reproductive health and gastroenterology. The firm, founded in 1950, operates in over 50 countries and is dedicated to fulfilling unmet clinical needs.
This recent expansion in gene therapy production not only strengthens Ferring's manufacturing capabilities but also ensures that the company remains at the forefront of innovative healthcare solutions, enhancing the lives of patients globally.
Frequently Asked Questions
What is Adstiladrin?
Adstiladrin, known as nadofaragene firadenovec-vncg, is an FDA-approved gene therapy for treating non-muscle invasive bladder cancer.
Where is the new manufacturing facility located?
The new facility is located in Kuopio, Finland, designed specifically for producing gene therapy drug substances.
Why is gene therapy important for cancer treatment?
Gene therapy can modify the behavior of cells to better fight cancer, enhancing the body’s natural defenses.
How does Adstiladrin work?
Adstiladrin works by delivering the interferon alfa-2b gene to bladder cells, helping to fight cancer more effectively.
What is Ferring Pharmaceuticals' mission?
Ferring Pharmaceuticals aims to build families and improve lives through innovative medical solutions, particularly in reproductive health and oncology.
